182 related articles for article (PubMed ID: 21054456)
1. Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug.
Kast RE
J Clin Pharm Ther; 2010 Dec; 35(6):657-63. PubMed ID: 21054456
[TBL] [Abstract][Full Text] [Related]
2. FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.
AIDS Alert; 2007 Sep; 22(9):103. PubMed ID: 18411462
[No Abstract] [Full Text] [Related]
3. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
[TBL] [Abstract][Full Text] [Related]
4. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.
MacArthur RD; Novak RM
Clin Infect Dis; 2008 Jul; 47(2):236-41. PubMed ID: 18532888
[TBL] [Abstract][Full Text] [Related]
5. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
Emmelkamp JM; Rockstroh JK
Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
[TBL] [Abstract][Full Text] [Related]
6. Maraviroc: a new CCR5 antagonist.
Sayana S; Khanlou H
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
[TBL] [Abstract][Full Text] [Related]
7. FDA panel backs HIV drug.
AIDS Read; 2007 Jun; 17(6):294. PubMed ID: 17632933
[No Abstract] [Full Text] [Related]
8. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
Hunt JS; Romanelli F
Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
[TBL] [Abstract][Full Text] [Related]
9. [CCR5 antagonist Maraviroc: effective and well tolerated. "A very promising substance"].
Zorn F
MMW Fortschr Med; 2011 May; 153(18):30-1. PubMed ID: 21604590
[No Abstract] [Full Text] [Related]
10. FDA approval: maraviroc.
Sax PE
AIDS Clin Care; 2007 Sep; 19(9):75. PubMed ID: 18398993
[No Abstract] [Full Text] [Related]
11. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
Bredeek UF; Harbour MJ
Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
[TBL] [Abstract][Full Text] [Related]
12. FDA approves maraviroc tablets.
AIDS Patient Care STDS; 2007 Sep; 21(9):702. PubMed ID: 17919097
[No Abstract] [Full Text] [Related]
13. Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro.
Wang X; Douglas SD; Lai JP; Tuluc F; Tebas P; Ho WZ
J Neuroimmune Pharmacol; 2007 Mar; 2(1):42-8. PubMed ID: 18040825
[TBL] [Abstract][Full Text] [Related]
14. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
15. Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 - 2008.
Yang H; Rotstein DM
Expert Opin Ther Pat; 2010 Mar; 20(3):325-54. PubMed ID: 20180619
[TBL] [Abstract][Full Text] [Related]
16. Something new under the sun. Maraviroc poised for approval.
Huff B
GMHC Treat Issues; 2006; 20(8-12):1-4. PubMed ID: 17569160
[No Abstract] [Full Text] [Related]
17. Maraviroc--new HIV drug. Emerging options need to be used wisely.
Vázquez E
Posit Aware; 2007; 18(4):18-9. PubMed ID: 17682275
[No Abstract] [Full Text] [Related]
18. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
Ndegwa S
Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
[TBL] [Abstract][Full Text] [Related]
19. HIV entry inhibitors: progress in development and application.
Lai WH; Huang L; Chen CH
Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
[TBL] [Abstract][Full Text] [Related]
20. CCR5 antagonist blocks metastasis of basal breast cancer cells.
Velasco-Velázquez M; Jiao X; De La Fuente M; Pestell TG; Ertel A; Lisanti MP; Pestell RG
Cancer Res; 2012 Aug; 72(15):3839-50. PubMed ID: 22637726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
